NVRO

ANALYST NOTE: NVRO (Nevro Corp.) Date: 2026-06-13 Current Price: $5.84

1. Structural Readiness

State: Context-only Conservative Entry: — Current Price: $5.84 Extension: — ATR at Breakout: — ATR Current: 0.7% (Sub-threshold) Pivot Strength: — Cap Bucket: Mid Sector: — Industry: —

Setup Analysis:

2. Thesis Layer

Thesis Classification: TACTICAL / Setup-Led Secular Exposure: None named at this date.

There is no named macro or secular thesis attached to NVRO as of this specific date. The investment case is strictly TACTICAL, driven by the quality of the technical setup and the immediate business fundamentals rather than a broad thematic tailwind. The conviction must be derived entirely from the structural readiness of the chart (the forming coil) and the operational progress of the company, without the benefit of a pre-existing narrative regarding market expansion or regulatory shifts.

3. Business Overview

Company Profile: Nevro Corp. is a medical technology firm focused on delivering solutions for individuals experiencing persistent pain. The company operates in the neuromodulation sector, specifically serving markets in the United States and globally.

Core Products & Technology: The company's core business revolves around the development and market introduction of the Senza spinal cord stimulation (SCS) system. This platform is engineered to alleviate chronic pain and includes newer generations such as the Senza II and Senza Omnia systems. A key differentiator is the proprietary 10 kHz Therapy, which is grounded in robust clinical evidence.

Market Status & Evidence (as of 2026-06-13):

• Product Launch History: Evidence from the 2024-11-11 earnings transcript confirms that the company received FDA approval for the HFX iQ with HFX AdaptivAI in September 2024 and announced a limited market release, with a full U.S. market launch scheduled for later that month.
• Adoption Metrics: As of the 2024-11-11 reporting period, more than 115,000 patients globally were using the 10-kilohertz SCS therapy.
• Market Opportunity: The company identifies the PDN (Post-Discectomy Neuropathy) market as significantly underpenetrated, estimated at less than 1%.
• Operational Efficiency: Through two restructurings earlier in 2024, the company removed more than $30 million in annual run-rate expenses from its cost structure.
• Revenue Guidance: In the 2024-11-11 transcript, management maintained full-year 2024 worldwide revenue guidance of approximately $400 million to $405 million, representing a 5% to 6% decrease from 2023 on both reported and constant currency bases.
• Distribution: Products are distributed via a dedicated direct sales team, specialized sales agents, and independent distributors.

4. Archetype and Conviction

Archetype: Growth Leader Rationale: NVRO fits the Growth Leader archetype based on its focus on advanced neuromodulation technology (Senza II, Senza Omnia) and the strategic expansion of its 10 kHz therapy platform. The removal of $30 million in annual expenses suggests a pivot toward operational efficiency to support future growth, while the underpenetrated PDN market offers a clear avenue for volume expansion.

Valuation & Financial Context: The financial spine data as of 2026-06-12 indicates a Forward consensus EPS of -2.08871 for FY1 and -1.92961 for FY2. This indicates that the company is currently operating at a loss, which is a significant headwind for a "Growth Leader" classification that typically implies profitability or a clear path to it. The negative earnings consensus suggests the market is pricing in future profitability that has not yet materialized.

Conviction Stack:

• Thesis Strength: Low (No named secular thesis; purely tactical).
• Evidence Quality: Moderate (Strong operational data from 2024, but financials show continued losses).
• Structural Quality: Moderate (Forming coil indicates stability, but low ATR suggests lack of momentum).
• Setup Readiness: Partial (Forming coil requires a breakout to become actionable).
• Rerating Potential: Dependent on the successful execution of the HFX iQ launch and the ability to turn the negative EPS consensus positive.

5. Invalidations, Strengths, and Gaps

What Would Invalidate the Case:

• Fundamental: Failure to achieve profitability or a significant widening of the loss gap beyond the current consensus could erode the "Growth Leader" narrative.

What Would Strengthen the Case:

• Technical: A confirmed breakout close above the resistance level (breakout firing) would convert the "Forming" status to "Confirmed-Active," validating the setup.
• Fundamental: Positive earnings surprises or guidance upgrades that move the EPS consensus toward breakeven would significantly improve the conviction stack.

Evidence Gaps:

• 2025-2026 Performance Data: The most recent earnings transcript is from November 2024. There is a lack of specific evidence regarding the actual sales performance of the HFX iQ system in 2025 and 2026, or the actual realization of the $30 million cost savings in the current fiscal year.
• Current Financials: While the financial spine provides forward consensus, there is no specific evidence of the company's actual Q1-Q2 2026 results or cash flow status as of June 2026.
• Sector/Industry Classification: The specific sector and industry labels are missing from the current data cache.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: low Key risks: Forward EPS consensus remains deeply negative (-2.08 FY1); Sub-threshold ATR (0.7%) indicates low volatility and lack of momentum; No named secular thesis to support rerating. Sizing hint: Position size should be minimal or zero until breakout confirmation; do not size based on forming coil alone. Expected path: Management expectations for HFX iQ adoption and cost structure efficiency must translate into revenue growth to offset losses; technical breakout required to trigger capital flow. Expected horizon: 3-6 months for potential breakout or invalidation.